Heart Transplant Clinical Trials

The care you'll receive at Cedars-Sinai, consistently ranked as the No. 1 heart transplant program in the U.S., is enhanced by the dedicated work of our cardiac specialists and researchers who have made pioneering advances in the field. As a Cedars-Sinai patient, you'll have the opportunity to participate in clinical trials that not only provide further treatment options, but also have the potential to create new lifesaving breakthroughs.

Questions? See the Clinical Trial FAQs.

18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes

Condition: 

Aortic Stenosis

Condition: 

Amyloidosis

Key Inclusion Criteria:

  • Adult males and females listed for heart transplant at collaborating institutions
  • Diagnosed with AL or TTR amyloidosis

Summary:

The purpose of this study is to collect data (medical information) on patients with light chain (AL) and transthyreitin (TTR) amyloidosis to assess health outcomes. In so doing, researchers aim to increase their understanding of disease presentation, progression, and various treatment plans for AL and TTR cardiac amyloidosis.

Condition: 

Heart Transplant

Key Inclusion Criteria:

  • Undergoing first allograft transplant
  • Men and non-pregnant women who are 18 to 70 years old
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to transplantation.

Summary:

The purpose of this study is to determine whether giving an investigational drug called thymoglobulin immediately after heart transplant for 5 days will prevent patients from developing a disease called cardiac allograft vasculopathy (CAV). In CAV, the blood vessels in the transplanted heart develop blockages. Thymoglobulin is a drug that works by suppressing the immune system; previous studies have suggested that thymoglobulin might prevent the development of CAV.

Condition: 

Coronary artery disease, peripheral vascular disease, cancers

Key Inclusion Criteria:

  • At least 18 years old with body mass index less than 30
  • Diagnosed with or undergoing evaluation for cardiovascular, nervous system diseases or solid-organ cancers

Summary:

Using the hybrid Siemens Biograph mMr (PET-MR) scanner, researchers simultaneously acquire MR and PET data across the whole body. Biomedical Imaging Research Institute scientists focus on developing new imaging techniques to answer a wide array of research and clinical questions, where producing a single scan that reveals both functional and anatomical information would create a more complete diagnostic tool. In collaboration with medical specialists, pulse sequences (software) are validated in patients undergoing evaluation for numerous diseases, including many types of heart disease, peripheral and intracranial (brain) neurological diseases, cancers, spine problems, urology and other nervous system disorders. The long-term goal of this study is to develop new techniques that would translate to clinical significance.

Condition:

Coronary Artery Disease

Key Inclusion Criteria:

  • Participants enrolled and to be enrolled in Barbra Streisand Women’s Heart Center research studies 

Summary:

The purpose of this study is to collect long-term data and blood and urine samples to further understand heart artery disease. In so doing, researchers aim to identify biomarker and genetic factors that influence heart arteries. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease. Participants will be contacted annually to complete a phone interview about topics such as clinical symptoms, medications, quality of life, hospitalizations, myocardial infarction (heart attack) and stroke.

Caisson Transcatheter Mitral Valve Replacement (TMVR) System Early Feasibility Study (PRELUDE)

Condition: 

Mitral Valve Regurgitation

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation (DUET)

Condition: 

Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction

Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

Condition: 

Cardiac Transplant Disorder

Condition: 

Atherosclerotic cardiovascular disease, hypercholesterolemia

Key Inclusion Criteria:

  • Evidence by cardiac computed tomography angiography of noncalcified coronary artery plaque and thoracic aorta atherosclerosis 
  • Indications for evolocumab treatment

Summary:

This study focuses on patients who have clinical atherosclerotic cardiovascular disease (ASCVD) or high cholesterol levels and are allergic to statins, or who have been diagnosed with primary hypercholesterolemia or homozygous familial hypercholesterolemia (genetic disorder causing high cholesterol levels and early heart disease). The purpose of the study is to evaluate the changes, if any, in coronary plaque volumes and its composition in patients who are treated with a drug called evolocumab. To help evaluate the effect of evolocumab, researchers will ask patients who are scheduled to start taking evolocumab plus another cholesterol-lowering medication (such as a statin) to undergo diagnostic testing, including non-invasive coronary computed tomography angiography scans and positron emission tomography (PET) scans.

Condition: 

Coronary artery disease

Key Inclusion Criteria:

  • At least 18 years old
  • Scheduled to undergo an invasive coronary angiography for the assessment of coronary artery disease at the time of enrollment
  • Signed consent form and willing to allow researchers to make medical records available to GE Healthcare

Summary:

This study focuses on patients who are scheduled to have an invasive coronary angiography (cardiac catheterization) as part of their standard of care. The purpose of the study is to evaluate how well an investigational imaging drug called flurpiridaz (F-18) can detect coronary artery disease. Coronary artery disease is a condition that decreases blood flow to the heart.

Condition: 

Atherosclerosis

Key Inclusion Criteria:

  • Recent myocardial infarction, ischemic stroke, or onset of symptomatic lower extremity peripheral artery disease less than 3 months before study enrollment
  • Recent or planned prescription of statin and antiplatelet therapy within 3 months of study recruitment

Summary:

This study focuses on patients who have recently had a heart attack, stroke or symptomatic peripheral artery disease. The purpose of the study is to measure plaque in multiple arteries in the body and evaluate their characteristics. Researchers will obtain these measurements to examine the ability of magnetic resonance imaging (MRI) to assess cardiovascular risk. Participants will undergo MRI of the carotid, coronary and femoral arteries; pulse wave analysis (a noninvasive clinical test) to measure stiffness of the blood vessels; and blood collection. They will also be asked to complete questionnaires.

Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment

Condition: 

Cardiovascular Disease, Atherosclerosis

Condition: 

Heart Transplant

Key Inclusion Criteria:

  • At least 21 years old
  • Greater than 12 months post-transplant
  • Able to read and write
  • Written informed consent
  • Physically able to participate in the study

Summary:

The purpose of this survey study is to examine how and if a heart transplant has affected quality of life in adult patients. The study will utilize a questionnaire to compare patient demographics, as well as physical, psychosocial, and economic information, to determine if there are any patterns between those factors and functional ability, lifestyle, marital status, work ability, satisfaction with transplant, quality of life, and clinical outcomes.

Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

Condition: 

Coronary Microvascular Dysfunction

Supporting Patients Undergoing High-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)

Condition: 

Coronary Artery Disease

Surveillance HeartCare® Outcomes Registry (SHORE)

Condition: 

Heart Transplant Rejection

Tocilizumab in Cardiac Transplantation

Condition: 

Heart Transplant

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (TROJAN-C)

Condition: 

Heart Failure

Women's Heart Attack Research Program—Imaging Study (HARP)

Condition:

Myocardial Infarction